PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: placebo
Drug: naproxen
Drug: valdecoxib

First Posted Date: 2008-04-01

Last Posted Date: 2008-07-21

Lead Sponsor: Pfizer

Target Recruit Count: 489

Registration Number: NCT00650455

Locations: 🇨🇦
Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada

A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring

Phase 3

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: propiverine
Drug: tolterodine PR

First Posted Date: 2008-03-31

Last Posted Date: 2008-03-31

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT00646880

Locations: 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of

A Study Of Diflucan In Children With Ringworm Of The Scalp

Phase 3

Completed

Conditions: Tinea Capitis

Interventions: Drug: fluconazole

First Posted Date: 2008-03-27

Last Posted Date: 2021-07-16

Lead Sponsor: Pfizer

Target Recruit Count: 185

Registration Number: NCT00645242

Locations: 🇵🇷
Pfizer Investigational Site, Ponce, Puerto Rico

Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: CP-945,598

First Posted Date: 2008-03-27

Last Posted Date: 2009-09-17

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT00645463

Locations: 🇺🇸
Pfizer Investigational Site, Ann Arbor, Michigan, United States

Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

Phase 1

Completed

Conditions: Obesity
Hepatic Insufficiency

Interventions: Drug: CP-945,598

First Posted Date: 2008-03-27

Last Posted Date: 2009-08-27

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00645021

Locations: 🇺🇸
Pfizer Investigational Site, Orlando, Florida, United States

Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: CP-945,598

First Posted Date: 2008-03-27

Last Posted Date: 2009-08-13

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT00644839

Locations: 🇺🇸
Pfizer Investigational Site, Miami, Florida, United States

Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: CP-945,598

First Posted Date: 2008-03-27

Last Posted Date: 2009-08-10

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT00645216

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

Phase 3

Completed

Conditions: Smoking Cessation

Interventions: Drug: placebo
Drug: varenicline (CP-526,555)

First Posted Date: 2008-03-27

Last Posted Date: 2011-04-15

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT00644969

Locations: 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults

Phase 3

Completed

Conditions: Pharyngitis
Tonsillitis

Interventions: Drug: azithromycin SR
Drug: azithromycin (Zithromax)
Drug: placebo

First Posted Date: 2008-03-26

Last Posted Date: 2011-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 598

Registration Number: NCT00644293

Locations: 🇬🇧
Pfizer Investigational Site, Kent, United Kingdom

A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery

Phase 2

Completed

Conditions: Pharmacokinetics

Interventions: Drug: azithromycin immediate release (Zithromax)
Drug: azithromycin SR
Other: placebo

First Posted Date: 2008-03-26

Last Posted Date: 2011-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00644176

Locations: 🇮🇹
Pfizer Investigational Site, Pisa, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy